Fahar Merchant

Company: Medicenna Therapeutics

Job title: President & Chief Executive Officer

Seminars:

Bizaxofusp in rGBM Patients Versus a Propensity Matched External Control Arm: Designing a Novel Phase 3 Trial with the FDA 9:30 am

Present design, mechanism, delivery and safety of bizaxofusp, an IL-4/IL-13R empowered superkine Summarize Phase 2b trial comparing bizaxofusp versus a propensity matched external control arm and effect of MGMT methylation, dose, IL4R expression, and combination with bevacizumab on median survival Overview of a novel Phase 3 registration trial using a Hybrid External Control ArmRead more

day: Conference Day One